

**Influence of antibiotic treatment on the detection of *S. aureus* DNA following
pre-analytical pathogen enrichment**

Supplemental Material

Matthias Pilecky¹, Anita Schildberger¹, Ludwig Knabl³, Dorothea Orth-Höller³ and Viktoria
Weber^{1,2}

¹Center for Biomedical Technology, Department for Health Sciences and Biomedicine, Danube
University Krems, Dr.-Karl-Dorrek-Strasse 30, 3500 Krems, Austria

²Christian Doppler Laboratory for Innovative Therapy Approaches in Sepsis, Department for
Health Sciences and Biomedicine, Danube University Krems, Dr.-Karl-Dorrek-Strasse 30,
3500 Krems, Austria

³Division of Hygiene and Medical Microbiology, Medical University of Innsbruck,
Schöpfstraße 41, A-6020 Innsbruck, Austria

Correspondence to:

Viktoria Weber, Department for Biomedical Research, Danube University Krems,
Dr.-Karl-Dorrek-Strasse 30, 3500 Krems, Austria

Tel.: +43 2732 893 2632

e-mail: viktoria.weber@donau-uni.ac.at

Table S1: Primers for qPCR used in this study.

Primer	Sequence
<i>S. aureus</i> forward	GTA AAA CTC TGT TAT TAG GGA AGA ACA TAT
<i>S. aureus</i> reverse	TAC CAG GGT ATC TAA TCC TGT TTG
human β -actin forward	CTG GAA CGG TGA AGG TGA CA
human β -actin reverse	AAG GGA CTT CCT GTA ACA ATG CA

Table S2: Minimal inhibitory concentrations of VAN, PIP, CIP, and CLI for the *S. aureus* strains used in this study.

Strain	Minimal inhibitory concentration [$\mu\text{g/mL}$]			
	VAN	PIP	CIP	CLI
12600	1.0	0.5	0.3	0.1
29213	0.5	8.0	0.3	<0.1
29737	0.3	0.1	0.1	<0.1
WT32217	0.3	0.1	0.1	<0.1
WT32237	4.0	0.3	0.5	0.1
WT32248	1.0	4.0	0.3	0.1

VAN: vancomycin, PIP: Piperacillin, CIP: Ciprofloxacin, CLI: Clindamycin